Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 May 2021 | Story André Damons | Photo Supplied
Scanning electron micrographs of Candida albicans (the large yeast cells) and Pseudomonas aeruginosa (the smaller bacterial cells). These are both opportunistic pathogens, that often co-occur in infections.

COVID-19 patients with severe symptoms who end up in intensive care units in hospitals are at risk of contracting an invasive fungal infection that might influence their outcomes and hamper treatment efforts. These fungal co-infections in COVID-19 patients on ventilators may contribute to the high mortality rate of these patients.

Prof Carlien Pohl-Albertyn and Dr Obinna Ezeokoli from the Pathogenic Yeast Research Group in the Department of Microbiology and Biochemistry, Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS), have recently published an article on the incidence of fungal infection in COVID-19 patients. They are also in the process of publishing another article on the potential risk factors of COVID-19 treatment for getting fungal infections.

Severe COVID-19 causes changes in the immune system

Prof Pohl-Albertyn, who is the NRF SARChI Research Chair in Pathogenic Yeasts, says there are several reasons why COVID-19 patients who end up with severe symptoms in intensive care units (ICUs) are at risk of fungal infections. 
“Severe COVID-19 causes changes in the immune system, such as increased release of cytokines (molecules involved in inflammation) and a decrease in certain white blood cells (which help to fight other infections). These changes might make patients more susceptible to invasive fungal infections. Severe SARS CoV-2 infection also damages the lung tissue, making it easier for inhaled fungi (such as Aspergillus species, Cryptococus neoformans, and mucoralean fungi) to cause invasive infections,” explains Prof Pohl-Albertyn.

Many of the patients with severe COVID-19, continues Prof Pohl-Albertyn, have other co-morbidities (including diabetes) that make them more susceptible to fungal infections. Patients with severe COVID-19 in ICUs are often ventilated and have central venous catheters as well as urinary catheters. These are also risk factors for fungal infections.
“Some drugs, such as corticosteroids used to treat the symptoms of severe COVID-19, may increase the risk of fungal infection – although the link between these drugs and fungal infection in COVID-19 has not been well studied yet. Some patients may be given broad-spectrum antibiotics to treat or prevent bacterial co-infection. These antibiotics could also kill the ‘good bacteria’ that help to keep the fungi in and on your body in check. If they are removed, the fungi that colonise the patients may overgrow and cause infection,” says Prof Pohl-Albertyn.

Any systemic fungal infection can be deadly

According to her, any systemic fungal infection can be deadly, so in patients with COVID-19 it is definitely cause for concern. In a recent study done on the tissue of patients who died from COVID-19 after long-term treatment, fungal infections were a constant finding in these patients, even though the infection was not detected while they were alive. One of the problems is that patients with severe COVID-19 are not routinely tested for fungal co-infection.

In their recent article published in the South African Medical Journal, Prof Pohl-Albertyn and Dr Ezeokoli write that the incidence of severe infection and mortality in COVID-19 is thought to be due in part to a lack of natural immunity and to viral replication in the lower respiratory tract, as well as superinfections, secondary infections, or co-infections (these terms are often used interchangeably), leading to severe lung injury and acute respiratory distress syndrome (ARDS).
“Co-infections with respiratory viruses (other than SARS-CoV-2), bacteria, and fungi have been reported in COVID-19 patients all over the world, and secondary infections have been identified as one of the predictors of a fatal outcome in COVID-19 cases. An earlier report from China suggests that the mortality rate for COVID-19 patients on ventilators in intensive care units (ICUs) is ~60%, and further indicated that invasive fungal co-infections may contribute to this high mortality. 

A South African perspective 

The researchers also report that studies conducted before the current COVID-19 pandemic have shown that fungal infections are highly prevalent in the South African population, partly owing to the high incidence of HIV.

According to their article, it was observed that the Candida carrier rate is higher in the South African population than elsewhere and that HIV-positive patients carry more, and a greater variety of pathogenic yeasts compared to HIV-negative subjects. Similarly, cryptococcal meningitis, caused by the Cryptococcus neoformans species complex, is one of the leading causes of HIV-related deaths in South Africa, with >135 900 deaths estimated for sub-Saharan Africa in 2014. 
Other fungal infections, including invasive aspergillosis, Pneumocystis pneumonia, and endemic mycoses, are also prevalent in South Africa. “Given the high prevalence of HIV/AIDS in South Africa as well as the high number of persons undergoing immunosuppressive therapies for other illnesses, co-infections with opportunistic fungal species may be affecting the current COVID-19 disease statistics in South Africa.” 

A serious fungal infection has the ability to kill you, and yet few people – especially those with a weakened immune system – are aware of this lurking danger. Just like bacteria, these minute life forms are becoming resistant to the handful of treatment options.

Prof Pohl-Albertyn and her team at the university are studying this neglected field, which annually claims the lives of 1,7 million people worldwide. It is estimated that more than 3,2 million South Africans are afflicted by fungal diseases each year.

News Archive

UFS gives recognition to excellent researchers
2004-11-16

p>The University of the Free State will give recognition to excellent researchers at UFS on Tuesday 16 November 2004. “This recognition function will also serve as the first annual lecture in research excellence,” says Prof Frans Swanepoel, Director of Research Development Division at the UFS.

 

This is the first occasion of its kind in the UFS. It coincides with the university’s centenary celebrations. The recognition of excellent research shows the UFS’s commitment and innovative focus on research as one of its core functions,” says Prof. Swanepoel.

Recognition will be given in different categories. They are female researchers, black researchers, young researchers, C- and L-Rated researchers, researchers with significant research outputs, B-Rated researchers and distinguished professors in research.

The promotion of equity and development of research capacity of designated groups is one of the objectives of the UFS’s research strategy therefore the university is recognising the research achievements of 21 women and 16 black persons. Amongst these are Prof. Margaret Raftery (English and Classical Languages), Dr Liesl van As (Zoology and Entomology), Prof. Peter Mbati (head of the Qwaqwa campus) and Prof. Charles Ngwena (Constitutional Law and Philosophy of Law).

The UFS is also recognising nine young researchers. They must hold a doctorate and have the potential to establish themselves as researchers within a five-year period based on their performance and productivity as researchers during their doctoral studies and/or early post-doctoral careers. Amongst them are Dr Esta van Heerden (Microbial Biochemical and Food Biotechnology) and Prof. André Jooste (Agricultural Economics).

Fifty-eight established researchers with a sustained recent record of productivity are receiving recognition in the C- and L-rated researchers’ category. Amongst them were Prof. Hennie van Coller (Afrikaans, Dutch, German and French) and Prof. Gert Erasmus (Animal- and Wildlife- and Grassland Sciences).

Prof. Francois Tolmie (New Testament) and Prof. Gina Joubert (Biostatistics) are two of the twelve researchers that are receiving recognition for having excelled in research outputs during recent years.

Nine researchers are acknowledged in the B-category for the international recognition they receive from their peers for the high quality and impact of their recent research outputs. Amongst them were Prof. Johan Grobbelaar (Plant Sciences) and Prof. Hendrik Swart (Physics). Prof. Grobbelaar focused in his research on limnology, algal biotechnology, plant stress and Prof. Swart focused on solid state physics and degradation mechanisms that are responsible for the degradation of field emission and TV displays.

Seven individuals are recognised for their exceptional achievements as researchers. Prof. Frederick Fourie, Rector, but previously in the Department of Economics, is recognised for his research in two policy areas: Political Economics, Government Finance and Fiscal Policy, and Industrial Economics, in particular analysis of the South African industrial structure and competition policy, where his research contributions played a key role in reforming South Africa’s competition policy.

Prof. Lodewyk Kock (Microbial, Biochemical and Food Biotechnology) focuses in his research mainly on pure and oxidised edible oil where yeasts are used as a study model. He obtained national as well as international recognition for this research program.

The UFS is also awarding the S2A3 Bronze Medal to recognise a Master’s degree student who has delivered outstanding research in one of the sciences. Mr Pieter Taljaard and Ms Tania Venter are recognised in this category.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
16 November 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept